Intellia Therapeutics (LTS:0JBU) Ending Cash Position : $185.58 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Intellia Therapeutics Ending Cash Position?

Intellia Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2024 was $185.58 Mil.

Intellia Therapeutics's quarterly Ending Cash Position increased from Sep. 2023 ($180.98 Mil) to Dec. 2023 ($240.35 Mil) but then declined from Dec. 2023 ($240.35 Mil) to Mar. 2024 ($185.58 Mil).

Intellia Therapeutics's annual Ending Cash Position increased from Dec. 2021 ($125.49 Mil) to Dec. 2022 ($535.46 Mil) but then declined from Dec. 2022 ($535.46 Mil) to Dec. 2023 ($240.35 Mil).

Intellia Therapeutics Ending Cash Position Historical Data

The historical data trend for Intellia Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intellia Therapeutics Ending Cash Position Chart

Intellia Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

57.23

164.61

125.49

535.46

240.35

Intellia Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial															306.11	183.76	180.98	240.35	185.58

Intellia Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Intellia Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	535.463	+	-295.11
	=	240.35

Intellia Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	240.353	+	-54.769
	=	185.58

Intellia Therapeutics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Intellia Therapeutics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Intellia Therapeutics (LTS:0JBU) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intellia Therapeutics Inc (LTS:0JBU) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

NTLA:USA 38I:Germany

Address

40 Erie Street, Suite 130, Cambridge, MA, USA, 02139

Website

https://www.intelliatx.com

Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Intellia Therapeutics (LTS:0JBU) Headlines

No Headlines